SCHEMBL13738315

SCHEMBL13738315

O=C(O)NCc1cccc(Cn2cc(Br)cn2)c1

nearest known ligand 0.62

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.62
▸ TSHR P16473 2/20 0.62
▸ ALDH1A1 P00352 3/20 0.51
▸ KDM4E B2RXH2 1/20 0.51
▸ HPGD P15428 1/20 0.49
▸ MAPK1 P28482 1/20 0.49
▸ KMT2A Q03164 1/20 0.49
▸ HSD17B10 Q99714 1/20 0.49
▸ POLB P06746 1/20 0.47
▸ TDP1 Q9NUW8 1/20 0.47
▸ L3MBTL1 Q9Y468 1/20 0.47
▸ KLKB1 P03952 9/20 0.47
▸ GAA P10253 1/20 0.46
▸ HTT P42858 1/20 0.46
▸ RAB9A P51151 1/20 0.46
▸ USP2 O75604 1/20 0.46
▸ PKM P14618 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ HDAC1 Q13547 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13736885 0.83 LMNA (0.55) LMNATSHRALDH1A1KDM4EHPGD
SCHEMBL13736854 0.80 POLB (0.71) LMNATSHRALDH1A1KDM4EHPGD
SCHEMBL13737296 0.76 TSHR (0.57) LMNATSHRALDH1A1KDM4EHPGD
SCHEMBL13739569 0.76 KMT2A (0.57) LMNATSHRALDH1A1KDM4EHPGD
SCHEMBL13736889 0.76 LMNA (0.61) LMNATSHRALDH1A1KDM4EHPGD
SCHEMBL2715134 0.76 HPGD (0.64) LMNATSHRALDH1A1KDM4EHPGD
SCHEMBL671242 0.75 TSHR (0.63) LMNATSHRALDH1A1KDM4EHPGD
Hydrochloric Acid SCHEMBL1852324 0.75 KMT2A (0.56) LMNATSHRALDH1A1KDM4EHPGD
SCHEMBL8059189 0.75 CYP1A2 (0.68) LMNATSHRALDH1A1KDM4EHPGD
SCHEMBL1750050 0.74 CYP1A2 (0.58) LMNATSHRHPGDKMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9062028-B2 Bicyclic nitrogen containing heteroaryl TGR5 receptor modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2015-06-23 — — US disclosed
US-20140080788-A1 NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS BRISTOL-MYERS SQUIBB COMPANY 2014-03-20 — — US disclosed
EP-2702042-A1 NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS Bristol-Myers Squibb Company (US) 2014-03-05 — — EP disclosed
WO-2012149236-A1 NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2012-11-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140080788-A1 NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS GRK5, GPBAR1, GPR55 LMNA 3285/4885TSHR 36/4885ALDH1A1 4427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback